Biofidelity’s Post

🫁As Australia prepares for the launch of the National Lung Cancer Screening Program next year, identifying strategies to ensure its success is critical to providing equitable access to this life-saving initiative. Key challenges include overcoming the stigma of lung cancer, addressing the geographical remoteness of screening sites, and adapting to varying epidemiological factors and healthcare resources across regions. Our upcoming webinar will explore practical strategies, share insights, and discuss best practices to enhance the quality and consistency of program implementation, aiming to improve participation and outcomes in lung cancer screening. #lungcancerscreening #rewritingcancer

Unlock the barriers to lung cancer screening (LCS). Experts will share strategies, insights, and best practices for improving quality and consistency of lung cancer screening implementation. Visit https://bit.ly/4h26Roc to register. #MadePossible #LungCancerScreening #RewritingCancer

We’re driven by science to change the way cancer is treated by pursuing novel small molecules that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK and FAK inhibition. If you are attending the International Gynecologic Cancer Society (IGCS) annual meeting, stop by our booth to learn more about our clinical research in this area. #IGSC2024 #KRAS #Cancerresearch #gynonc #VerastemOnc

An exciting breakthrough step forward in early and easy detection of lung cancer, which kills more men and women each year than any other cancer! In cancer, it’s almost always about early detection, and this test appears to help! Looking forward to this test becoming mainstream, and Delfi moving on to develop other early detection cancer tests! Go Delfi!

Why is it critical to wait for biomarker results in non-small cell lung cancer (#NSCLC) and what challenges and issues does it create? Check out the latest discussion featuring International Association for the Study of Lung Cancer’s Stephen Liu and esteemed guests https://hubs.ly/Q02F26kn0

An interesting discussion about how AI might help the future of lung cancer screening. Anything we can do to detect lung cancer earlier and provide more opportunities for screening is critical to our patients. https://lnkd.in/gdk2UYtf

🔬 Discover the future of #cancertherapy with our innovative ATACs! 🔬   "Our payload is different...we truly believe that the long-term response is improved with the application of ATACs into cancer therapy with a mechanism of cytotoxicity which is radically different from conventional chemotherapy."   Watch the full webinar to learn more from Heidelberg Pharma AG CEO, Andreas Pahl about how we're revolutionizing cancer treatment, alongside Key Opinion Leaders in the ADC field, Jonathan Kaufman and Rakesh Dixit, Ph.D., DABT: 📌 https://lnkd.in/eVJygzyn   #ADCs #ATAC #CancerResearch

#DidYouKnow that there were approximately 2.4 million documented cases of lung cancer globally, with Non-Small Cell Lung Cancer (NSCLC) accounting for 2.1 million cases? Since 2019, more than 5,000 NSCLC clinical trials have been initiated globally. The Asia-Pacific region leads with 41%, followed by North America at 32%, Europe at 19%, and the rest of the world at 8%. This comprehensive report provided by the Novotech analyst team is free of charge. Want to learn more? Download the latest report. https://lnkd.in/dw9C4Fhm #NSCLC #ClinicalResearch #Novotech

On World Lung Cancer Day, we stand with everyone affected by lung cancer, emphasizing the importance of research, early detection, and availability of novel treatments for better patient outcomes. We are investigating our hexavalent OX40 agonist, #INBRX106, in Non-Small Cell Lung Cancer (NSCLC) in our actively enrolling Phase 1 study. Inhibrx is committed to advancing research in lung cancer in the hopes of identifying potential new treatment options. Learn more about our actively enrolling clinical trial here: https://bit.ly/49ZyYks #Inhibrx #BioTechnology

Our partner physician group, GI CONNECT had launched this insightful video Update From ESMO 2024 covering the latest data on Lower GI cancer. Watch the first video here....